Navigation Links
Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
Date:6/10/2008

PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it has signed a license and supply agreement with NATCO Pharma Ltd. (NATCO) for NATCO's glatiramer acetate pre-filled syringes, a generic version of Teva's Copaxone(R), which is used to treat multiple sclerosis. The agreement grants Mylan exclusive distribution rights in the United States and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand into additional territories.

NATCO has commercialized successfully its glatiramer acetate product in India and the Ukraine. Teva has reported that worldwide sales of Copaxone were more than $1.7 billion in 2007.

"We are extremely pleased to be collaborating with NATCO to market and distribute this critically important product virtually worldwide," said Robert J. Coury, Mylan vice chairman and CEO. "We've worked closely with NATCO over the past several months, and we're excited to have completed this agreement. During that time, we have been impressed with the company's long-term vision and outstanding technical capabilities, which are clearly reflected in NATCO's ability to develop a complex product such as generic Copaxone. We plan to work closely with all relevant regulatory agencies in the United States and internationally -- and leverage Mylan's considerable global expertise in regulatory applications -- to bring the therapeutic and economic benefits of this product to the widest possible patient-base."

"We had spoken with several potential partners since we launched glatiramer as a generic in India last year," said NATCO Chairman and Managing Director Chowadary V. Nannapaneni. "After an extensive review, we believe that no company is better positioned than Mylan to help us unlock the extraordinary value of this product in the United States and around the world. We are truly excited about our collaboration."

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies

NATCO Pharma Limited, based in Hyderabad, India, is ranked among the fastest growing pharmaceutical companies in the country. It manufactures branded and generic dosage forms, bulk actives and intermediates for Indian and international markets. During its 24-year history, NATCO has gained a reputation for innovative product development, high-quality manufacturing capabilities and strong financial growth.

Copaxone(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Announces Final FDA Approval for Zaleplon Capsules
2. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
3. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
4. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
5. Mylan Declares Quarterly Preferred Stock Dividend
6. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
7. Mylan Announces Final FDA Approval for Trandolapril Tablets
8. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
9. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
10. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
11. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... (PRWEB) , ... April 23, 2017 , ... ... and managed services announced the achievement of Cisco Select certification and SMB specialization. ... the United States. , In earning the Select Certification, Altura fulfilled ...
(Date:4/22/2017)... , ... April 22, 2017 , ... The San Juan Capistrano summer camp ... parenting report outlining the need for summer camps to provide physical activities for all campers. ... Physical Activity In Summer Camps , With an increase in specialty camps that focus on ...
(Date:4/21/2017)... ... , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , has ... bony lump located on the forehead usually attributed to a facial fracture. Their appearance ... Dr. Shah has discovered an approach that is minimally invasive. He is an expert ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
(Date:4/21/2017)... Sterling, VA (PRWEB) , ... April 21, 2017 ... ... hosting its first weeklong campaign, AWARE: A Week of Addiction and Recovery Education, ... emerging evidence in treating and preventing substance use disorders. , The mission ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology: